4D MOLECULAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26 USD | +2.60% |
|
+1.68% | +28.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 3.63M | Sales 2025 * | 6.18M | Capitalization | 1.34B |
|---|---|---|---|---|---|
| Net income 2024 * | -158M | Net income 2025 * | -191M | EV / Sales 2024 * | 232 x |
| Net cash position 2024 * | 502M | Net cash position 2025 * | 403M | EV / Sales 2025 * | 152 x |
| P/E ratio 2024 * |
-8.58
x | P/E ratio 2025 * |
-8.81
x | Employees | 171 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on 4D Molecular Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.60% | ||
| 1 week | +1.68% | ||
| Current month | +8.65% | ||
| 1 month | +2.97% | ||
| 3 months | -5.07% | ||
| 6 months | +109.85% | ||
| Current year | +28.33% |
1 week
24.36
27.17
1 month
22.7527.84
Current year
16.6436.25
1 year
9.4436.25
3 years
5.3236.25
5 years
5.3255.11
10 years
5.3255.11
| Managers | Title | Age | Since |
|---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 14 M€ | -2.76% | ||
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 26 | +2.60% | 462,605 |
| 24-05-17 | 25.34 | -1.17% | 438,654 |
| 24-05-16 | 25.64 | +0.23% | 526,900 |
| 24-05-15 | 25.58 | -0.66% | 429,968 |
| 24-05-14 | 25.75 | +0.70% | 425,599 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotes
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
04:00pm
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26
USD
Average target price
52.3
USD
Spread / Average Target
+101.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.33% | 1.34B | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +49.62% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B |
- Stock Market
- Equities
- FDMT Stock
